ORIGINAL ARTICLE
Molecular classification of diffuse gliomas
1
Department of Pathology, Riga Stradins University, Riga, Latvia
2
Department of Surgery, Riga Stradins University, Riga, Latvia
Submission date: 2019-09-30
Acceptance date: 2020-02-10
Publication date: 2020-03-06
Pol J Pathol 2019;70(4):246-258
KEYWORDS
TOPICS
ABSTRACT
In this study we assessed whether gliomas could be subdivided into different molecular subtypes by immunohistochemistry (IHC) reminiscent of those first described by Verhaak et al. in 2010 (classical, proneural, mesenchymal and neural). We also evaluated the prognostic significance of single molecular factors and searched for significant correlations between markers. In this study, we included 146 patients with glioblastomas (GBMs) and 26 with diffuse astrocytomas (DAs). The glioma samples were tested for PDGFRA, IDH1 R132H, CD44, p53, Ki-67, p21 and p27 expression. We found that gliomas could be subdivided into molecular subtypes by IHC. Fifty per cent of GBMs were of the proneural subtype, 18.5% of mesenchymal subtype and 31.5% were not otherwise classified. However, most of the DAs (92.3%) belonged to the proneural subtype. No prognostic role was found for the molecular subtypes, but predictive roles were noted. Both proneural and mesenchymal molecular subtypes showed a benefit from the addition of chemotherapy and radiotherapy; however, the mesenchymal subtype showed a greater response. Interestingly, the mesenchymal subtype did not receive any benefit from the addition of radiotherapy compared with palliative management and surgery alone. Regarding single molecular markers, only IDH1 R132H was found to have a prognostic role for GBMs. There was a trend towards better survival in tumours with lower PDGFRA expression (p = 0.066). In DAs, PDGFRA and Ki-67 expression had prognostic roles. The following statistically significant correlations were found in GBMs: Ki-67/p53, Ki-67/p27 and p53/PDGFRA; in DAs: p53/PDGFRA, CD44/PDGFRA, and p21/PDGFRA.
REFERENCES (37)
1.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. Fourth Edition ed; 2016.
2.
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
3.
Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
4.
Brennan C, Momota H, Hambardzumyan D, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PloS One 2009; 4: e7752.
5.
Popova SN, Bergqvist M, Dimberg A, et al. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology 2014; 64: 365-379.
6.
Le Mercier M, Hastir D, Moles Lopez X, et al. A simplified approach for the molecular classification of glioblastomas. PloS One 2012; 7: e45475.
7.
Motomura K, Natsume A, Watanabe R, et al. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci 2012; 103: 1871-1879.
8.
Yoshida T, Matsuda Y, Naito Z, Ishiwata T. CD44 in human glioma correlates with histopathological grade and cell migration. Pathol Int 2012; 62: 463-470.
9.
Kwiatkowska A, Symons M. Signaling determinants of glioma cell invasion. Adv Exp Med Biol 2013; 986: 121-141.
10.
Zhang Q, Guo W, Di C,et al. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell. Pol J Pathol 2017; 68: 312-317.
11.
Jesionek-Kupnicka D, Szybka M, Potemski P, et al. Association of loss of heterozygosity with shorter survival in primary glioblastoma patients. Pol J Pathol. 2013; 64: 268-275.
12.
Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
13.
Teo WY, Sekar K, Seshachalam P, et al. Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifier among Patient Populations. Sci Rep 2019; 9: 7442.
14.
Olmez I, Love S, Xiao A, et al. Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neurooncology 2018; 20: 192-202.
15.
Stringer BW, Day BW, D’Souza RCJ, et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Sci Rep 2019; 9: 4902.
16.
Behnan J, Finocchiaro G, Hanna G. The landscape of the mesenchymal signature in brain tumours. Brain 2019; 142: 847-866.
17.
Bhat KP, Balasubramaniyan V, Vaillant B, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 2013; 24: 331-346.
18.
Nagy A, Garzuly F, Padanyi G, et al. Molecular Subgroups of Glioblastoma – an Assessment by Immunohistochemical Markers. Pathol Oncol Res 2019; 25: 21-31.
19.
Fudyma IA, Wadhwani NR. Medulloblastoma with extensive nodularity (SHH medulloblastoma). Pol J Pathol 2017; 68: 364-366.
20.
Lin N, Yan W, Gao K, et al. Prevalence and Clinicopathologic Characteristics of the Molecular Subtypes in Malignant Glioma: A Multi-Institutional Analysis of 941 Cases. PloS One 2014; 9: e94871.
21.
Brown DV, Daniel PM, D’Abaco GM, et al. Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme. Oncotarget 2015; 6: 6267-6280.
22.
Cheng WY, Kandel JJ, Yamashiro DJ, et al. A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PloS One 2012; 7: e34705.
23.
Mao P, Joshi K, Li J, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A 2013; 110: 8644-8649.
24.
Nakano I. Stem cell signature in glioblastoma: therapeutic development for a moving target. J Neurosurg 2015; 122: 324-330.
25.
Fedele M, Cerchia L. Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma. Int J Mol Sci 2019; 20: pii: E2746.
26.
Cooper LA, Gutman DA, Long Q, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PloS One 2010; 5: e12548.
27.
Guan X, Vengoechea J, Zheng S, et al. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PloS One 2014; 9: e91216.
28.
Kim Y-H, Nobusawa S, Mittelbronn M, et al. Molecular Classification of Low-Grade Diffuse Gliomas. Am J Pathol 2010; 177: 2708-2714.
29.
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002-6007.
30.
Gravendeel LA, Kloosterhof NK, Bralten LB, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 2010; 31: E1186-1199.
31.
Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4154.
32.
Cohen A, Holmen S, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013; 13: 345-345.
33.
Gondim DD, Gener MA, Curless KL, et al. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction. Appl Immunohistochem Mol Morphol 2019; 27: 722-725.
34.
Kato Y. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol 2015; 32: 3-11.
35.
Martinho O, Longatto-Filho A, Lambros MB, et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br J Cancer 2009; 101: 973-982.
36.
Trembath D, Miller CR, Perry A. Gray zones in brain tumor classification: evolving concepts. Adv Anat Pathol 2008; 15: 287-297.
37.
Conroy S, Kruyt FA, Joseph JV, et al. Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach. PloS One 2014; 9: e115687.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
